Microdose: Off-label ketamine, Spravato and the future of ketamine treatment for depression

This is an interesting article for Microdose I was recently a part of. It reviews the history of ketamine and how the medical world has began to embrace ketamine not just for on-label use as an anesthetic, but also for off-label uses in the treatment of mental illnesses, like depression, given the rapid antidepressant characteristics of ketamine. I also share my insights on Spravato vs. Ketamine and how the FDA, insurance companies, and other groups play into decisions made by providers and patients. “Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity."